Next-Gen Dermatology Treatments Market Size, Report by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Next-Gen Dermatology Treatments Market

5.1. COVID-19 Landscape: Next-Gen Dermatology Treatments Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Next-Gen Dermatology Treatments Market, By Treatment Type

8.1. Next-Gen Dermatology Treatments Market Revenue and Volume Forecast, by Treatment Type

8.1.1. Biologics & Targeted Therapies

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Energy-based Devices

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Regenerative Therapies

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Personalized Topical & Oral Therapies

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Medical Aesthetics

8.1.5.1. Market Revenue and Volume Forecast

Chapter 9. Global Next-Gen Dermatology Treatments Market, By Indication

9.1. Next-Gen Dermatology Treatments Market Revenue and Volume Forecast, by Indication

9.1.1. Psoriasis & Atopic Dermatitis

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Alopecia Areata & Vitiligo

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Aesthetic Indications (skin tightening, wrinkle reduction, pigmentation correction)

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Melasma, Hyperpigmentation, and Scarring

9.1.4.1. Market Revenue and Volume Forecast

Chapter 10. Global Next-Gen Dermatology Treatments Market, By Delivery Platform

10.1. Next-Gen Dermatology Treatments Market Revenue and Volume Forecast, by Delivery Platform

10.1.1. Injectables

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Topical Advanced Formulations

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Device-based Non-invasive Systems

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Digital Therapeutics & AI Dermatology Apps

10.1.4.1. Market Revenue and Volume Forecast

Chapter 11. Global Next-Gen Dermatology Treatments Market, By End User

11.1. Next-Gen Dermatology Treatments Market Revenue and Volume Forecast, by End User

11.1.1. Dermatology Clinics & MedSpas

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Hospitals / Skin Care Departments

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Home-use Devices / DTC Models

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Teledermatology Platforms

11.1.4.1. Market Revenue and Volume Forecast

Chapter 12. Global Next-Gen Dermatology Treatments Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Treatment Type

12.1.2. Market Revenue and Volume Forecast, by Indication

12.1.3. Market Revenue and Volume Forecast, by Delivery Platform

12.1.4. Market Revenue and Volume Forecast, by End User

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Treatment Type

12.1.5.2. Market Revenue and Volume Forecast, by Indication

12.1.5.3. Market Revenue and Volume Forecast, by Delivery Platform

12.1.5.4. Market Revenue and Volume Forecast, by End User

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Treatment Type

12.1.6.2. Market Revenue and Volume Forecast, by Indication

12.1.6.3. Market Revenue and Volume Forecast, by Delivery Platform

12.1.6.4. Market Revenue and Volume Forecast, by End User

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Treatment Type

12.2.2. Market Revenue and Volume Forecast, by Indication

12.2.3. Market Revenue and Volume Forecast, by Delivery Platform

12.2.4. Market Revenue and Volume Forecast, by End User

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Treatment Type

12.2.5.2. Market Revenue and Volume Forecast, by Indication

12.2.5.3. Market Revenue and Volume Forecast, by Delivery Platform

12.2.5.4. Market Revenue and Volume Forecast, by End User

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Treatment Type

12.2.6.2. Market Revenue and Volume Forecast, by Indication

12.2.6.3. Market Revenue and Volume Forecast, by Delivery Platform

12.2.6.4. Market Revenue and Volume Forecast, by End User

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Treatment Type

12.2.7.2. Market Revenue and Volume Forecast, by Indication

12.2.7.3. Market Revenue and Volume Forecast, by Delivery Platform

12.2.7.4. Market Revenue and Volume Forecast, by End User

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Treatment Type

12.2.8.2. Market Revenue and Volume Forecast, by Indication

12.2.8.3. Market Revenue and Volume Forecast, by Delivery Platform

12.2.8.4. Market Revenue and Volume Forecast, by End User

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Treatment Type

12.3.2. Market Revenue and Volume Forecast, by Indication

12.3.3. Market Revenue and Volume Forecast, by Delivery Platform

12.3.4. Market Revenue and Volume Forecast, by End User

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Treatment Type

12.3.5.2. Market Revenue and Volume Forecast, by Indication

12.3.5.3. Market Revenue and Volume Forecast, by Delivery Platform

12.3.5.4. Market Revenue and Volume Forecast, by End User

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Treatment Type

12.3.6.2. Market Revenue and Volume Forecast, by Indication

12.3.6.3. Market Revenue and Volume Forecast, by Delivery Platform

12.3.6.4. Market Revenue and Volume Forecast, by End User

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Treatment Type

12.3.7.2. Market Revenue and Volume Forecast, by Indication

12.3.7.3. Market Revenue and Volume Forecast, by Delivery Platform

12.3.7.4. Market Revenue and Volume Forecast, by End User

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Treatment Type

12.3.8.2. Market Revenue and Volume Forecast, by Indication

12.3.8.3. Market Revenue and Volume Forecast, by Delivery Platform

12.3.8.4. Market Revenue and Volume Forecast, by End User

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Treatment Type

12.4.2. Market Revenue and Volume Forecast, by Indication

12.4.3. Market Revenue and Volume Forecast, by Delivery Platform

12.4.4. Market Revenue and Volume Forecast, by End User

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Treatment Type

12.4.5.2. Market Revenue and Volume Forecast, by Indication

12.4.5.3. Market Revenue and Volume Forecast, by Delivery Platform

12.4.5.4. Market Revenue and Volume Forecast, by End User

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Treatment Type

12.4.6.2. Market Revenue and Volume Forecast, by Indication

12.4.6.3. Market Revenue and Volume Forecast, by Delivery Platform

12.4.6.4. Market Revenue and Volume Forecast, by End User

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Treatment Type

12.4.7.2. Market Revenue and Volume Forecast, by Indication

12.4.7.3. Market Revenue and Volume Forecast, by Delivery Platform

12.4.7.4. Market Revenue and Volume Forecast, by End User

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Treatment Type

12.4.8.2. Market Revenue and Volume Forecast, by Indication

12.4.8.3. Market Revenue and Volume Forecast, by Delivery Platform

12.4.8.4. Market Revenue and Volume Forecast, by End User

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Treatment Type

12.5.2. Market Revenue and Volume Forecast, by Indication

12.5.3. Market Revenue and Volume Forecast, by Delivery Platform

12.5.4. Market Revenue and Volume Forecast, by End User

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Treatment Type

12.5.5.2. Market Revenue and Volume Forecast, by Indication

12.5.5.3. Market Revenue and Volume Forecast, by Delivery Platform

12.5.5.4. Market Revenue and Volume Forecast, by End User

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Treatment Type

12.5.6.2. Market Revenue and Volume Forecast, by Indication

12.5.6.3. Market Revenue and Volume Forecast, by Delivery Platform

12.5.6.4. Market Revenue and Volume Forecast, by End User

Chapter 13. Company Profiles

13.1. Amgen

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial PerTreatment Typeance

13.1.4. Recent Initiatives

13.2. Sanofi & Regeneron

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial PerTreatment Typeance

13.2.4. Recent Initiatives

13.3. Almirall

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial PerTreatment Typeance

13.3.4. Recent Initiatives

13.4. Candela

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial PerTreatment Typeance

13.4.4. Recent Initiatives

13.5. Johnson & Johnson (Neutrogena Skin360)

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial PerTreatment Typeance

13.5.4. Recent Initiatives

13.6. DermaSensor

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial PerTreatment Typeance

13.6.4. Recent Initiatives

13.7. Forefront Dermatology / U.S. Dermatology Partners

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial PerTreatment Typeance

13.7.4. Recent Initiatives

13.8. SkinCeuticals / Skinbetter Science

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial PerTreatment Typeance

13.8.4. Recent Initiatives

13.9. CureSkin, Remedico, SkinAI (India)

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial PerTreatment Typeance

13.9.4. Recent Initiatives

13.10. Revance

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial PerTreatment Typeance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The major players in the mext-gen dermatology treatments market include AbbVie (Allergan), Eli Lilly, Amgen, Sanofi & Regeneron, Leo Pharma, UCB Pharma, Incyte, Pfizer, Almirall, Revance, Cutera, Candela, Lumenis, Venus Concept, L’Oréal Active Cosmetics, Johnson & Johnson (Neutrogena Skin360), DermaSensor, Forefront Dermatology / U.S. Dermatology Partners, SkinCeuticals / Skinbetter Science, and CureSkin, Remedico, SkinAI (India).

The driving factors of the mext-gen dermatology treatments market are the rising incidence of skin diseases, such as eczema, psoriasis, and skin cancer, drives the need for advanced dermatological treatments and diagnostics that are effective, accurate, durable, and targeted.

North America region will lead the global mext-gen dermatology treatments market during the forecast period 2025 to 2034.